Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Alliance Global Partners Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $8.5

Author: Benzinga Newsdesk | February 16, 2024 08:59am
Alliance Global Partners analyst Scott Henry initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $8.5.

Posted In: DERM